.png)
Impact on patients and pharma companies
The solution reduces hospitalization and readmissions through early intervention and proactive treatment, while enhancing patient engagement with intuitive home-based telehealth tools. It also provides pharmaceutical companies with continuous real-world evidence through longitudinal data collection, offering valuable insights into drug efficacy, digital phenotyping, and post-market surveillance. This innovative approach supports better care delivery and fosters data-driven decision-making for improved patient outcomes.
Versatile AI Voice Solution for Seamless Health Monitoring
Our AI-driven voice biomarker solution is seamlessly integrated into a user-friendly mobile app, making it easy for patients to incorporate into their daily lives. This smartphone-based approach eliminates the need for complex devices, enabling non-invasive, real-time health tracking anytime, anywhere. Designed for high engagement, even among older users, studies show adherence rates of up to 87%. While primarily app-based, the solution also supports offline audio recording with later analysis or cloud-based processing for broader insights. Additionally, it can be deployed as a monitoring and follow-up tool during medication testing, expanding its clinical applications beyond routine health tracking.
Incorporating voice biomarkers as secondary or exploratory endpoints in ongoing or upcoming clinical trials.
Integrating voice biomarkers as secondary or exploratory endpoints in clinical trials offers a novel, non-invasive way to monitor disease progression, treatment response, and patient well-being. By analyzing subtle voice changes, researchers can gain real-time, objective insights into a patient’s condition, complementing traditional clinical assessments. This approach is particularly valuable in respiratory and cardiovascular diseases, where vocal characteristics can reflect physiological changes before symptoms become clinically apparent. Incorporating voice biomarkers into trials enables continuous remote monitoring, improves data richness, and may help identify early indicators of treatment efficacy or adverse events, ultimately enhancing clinical decision-making and patient outcomes.
Participating in a planned study involving COPD patients.
This collaboration brings together three expert partners: (i) a Germany-based digital healthcare company leveraging voice and technology to enhance health and care, (ii) a Spain-based telehealth platform company strengthening connections between patients and healthcare professionals, and (iii) a University Hospital in Argentina. The study aims to evaluate a solution that integrates voice biomarkers with telehealth, enabling continuous patient monitoring, early detection of exacerbation risks, and actionable insights for healthcare providers. With a demonstrated ability to predict 84% of COPD exacerbations in advance, this innovative system has the potential to revolutionize disease management and improve patient outcomes.
Participating in a planned study involving COPD patients.
This collaboration brings together three expert partners: (i) a Germany-based digital healthcare company leveraging voice and technology to enhance health and care, (ii) a Spain-based telehealth platform company strengthening connections between patients and healthcare professionals, and (iii) a University Hospital in Argentina. The study aims to evaluate a solution that integrates voice biomarkers with telehealth, enabling continuous patient monitoring, early detection of exacerbation risks, and actionable insights for healthcare providers. With a demonstrated ability to predict 84% of COPD exacerbations in advance, this innovative system has the potential to revolutionize disease management and improve patient outcomes.
How can you benefit?
Gain a competitive edge by adopting cutting-edge voice biomarker technology
Improve trial efficiency with real-time, remote symptom tracking
Enhance patient engagement through low-burden monitoring
Generate robust real-world evidence to support regulatory submissions
Position your company as a leader in digital health innovation
How can you contribute?
-
Provide co-funding to support the planned clinical validation studies in COPD and Heart Failure.
-
Contribute with resources to accelerate the regulatory path and facilitate real-world validation of the technology.
-
Back the initiative to help bring non-invasive, voice-based monitoring tools to clinical trials and routine care faster.
What can DEEP offer?
The DEEP services and collaboration tools equip teams working in DEEP with everything they need to develop digital measures and enable more efficient collaboration along the way. The DEEP digital measure builder, powered by the Stack model, is a framework that enables structuring of evidence, the identification of evidence gaps and efficient information exchange with regulators. The stack model also promotes content reuse across new solutions or contexts of use.
-
Access to a ready-to-use voice biomarker technology
-
Option to join or co-fund pre-planned studies in COPD and HF
-
Involvement in shaping regulatory dialogue and validation frameworks
-
Strategic position in the digital health ecosystem
Next Steps
Connect with us if you are interested in learning more about these, or other missions.
Strategic Partnership Opportunity:
Advance Voice Biomarker Technology in COPD and Heart Failure
DEEP is launching a new initiative focused on advancing AI-driven voice biomarkers in COPD and HF. Developed by Zana, this technology enables real-time, non-invasive health monitoring through simple daily voice tasks. The solution can detect early signs of COPD exacerbations and HF decompensation by analyzing subtle changes in vocal patterns. Its integration into trials provides meaningful, objective insights into patient conditions and improves endpoint data quality. This mission will explore the application of voice biomarkers in clinical trial settings, paving the way for regulatory acceptance and broader use in respiratory and cardiovascular care.
We are looking for pharmaceutical companies focused on COPD and HF who are ready to:
-
Integrate voice biomarkers into ongoing or upcoming clinical trials
-
Join an active effort to validate these biomarkers both analytically and clinically
-
Help shape future regulatory pathways through real-world application
The AI-powered Voice Measure Solution
Built on artificial intelligence and validated through multiple research studies, our voice biomarker technology enables patients to monitor their health effortlessly—anytime, anywhere—through simple voice tasks such as journaling, sustained vowel sounds, and text reading.